The rise of antimicrobial resistant (AMR) bacterial infections and cancer are two of the greatest health threats facing humanity today. A report generated in 2014 attributed 8.8 million deaths to cancer in that year alone, while simultaneously predicting that by the year 2050, ten million people per year will die from the primary effects of AMR. The present impact of AMR was confirmed by a recent study, which reported 4.95 million and 1.27 million deaths from the indirect and direct effects of AMR respectively during 2019. This means that over this time period, AMR was directly responsible for the same number, if not more deaths than those directly attributed to either HIV/AIDs or malaria. This rise in AMR has traditionally been attributed to the misuse of antimicrobial agents, including antibiotics, across multiple sectors. In addition, although we do not yet truly understand the impacts of the COVID-19 pandemic on increased rate of AMR infections, there was a high level of AMR bacterial co-infections confirmed within patients suffering from COVID-19 over the first 18 months of the pandemic. Given the serious health threat that antimicrobial resistance (AMR) poses now and in the future, there has been a focused effort to develop new antimicrobial agents. This has led to the approval of 12 new antibiotics for use within the clinic (2017-2021), with a further 45 in the clinical development pipeline, 27 of which target WHO priority pathogens. 9 However, this level of innovation still does not fulfil current or future global need. In 2020, there were an estimated 19.3 million new cancer cases identified and almost 10 million cancer-related deaths worldwide. There is no doubt that the burden of cancer is growing globally, due to the aging population, types of risk factors, and rise of resistance to commonly marketed therapeutic agents. In 2020, 313,959 new ovarian cancer cases were reported globally. The number of ovarian cancer-related deaths in this same year was 207,252 (2.1 % of all cancer deaths). The high mortality figures for ovarian cancer are in part due to the fact that approximately 70 % of all diagnoses occur at an advanced stage of the disease, reducing patient survival rates. The high mortality figures are also due to the common use of platinum and taxane-based chemotherapeutic agents, which often lead to complications and resistance, causing 70 % of patients to develop disease recurrence with resistance to these therapeutic agents. Due to the expense associated with developing novel drugs, there is much interest in repurposing currently approved therapies to treat different diseases. Interestingly, a number of antimicrobial agents are reported to have off target activity for the treatment of cancer e.g. tetracyclines and fluoroquinolones. However, as well as providing a novel route for the low cost identification of novel cancer agents, the identification of agents with both antimicrobial and anticancer activity may have other advantages for the treatment of cancer patients. Microbial infection is a significant cause of morbidity and mortality in cancer patients, due to general immunosuppression including febrile neutropenia, caused by the effect of the cancer on the human body and/or induced by cancer drug treatment, tumour obstruction or surgery. Of the chemotherapy regimens used to treat ovarian cancer, topotecan, docetaxel and paclitaxel all place a patient at significant risk of febrile neutropenia. Therefore, the gold standard treatment here should be one that treats the cancer, treats infectious disease and can overcome resistance in both diseases simultaneously.